WO2022183964A1

WO2022183964A1 - 8-(pyridine triazole) substituted coumarin-type compound, and preparation method therefor and application thereof

Info

Publication number: WO2022183964A1
Application number: PCT/CN2022/077641
Authority: WO
Inventors: 李燕; 陈晓光; 张小曦
Original assignee: 朗捷睿(苏州)生物科技有限公司
Priority date: 2021-03-05
Filing date: 2022-02-24
Publication date: 2022-09-09
Also published as: WO2022183964A9; CN113149970A; CN113149970B

Abstract

The present application relates to a 8-(pyridine triazole) substituted coumarin-type compound, and a preparation method therefor and an application thereof. The structure of the 8-(pyridine triazole) substituted coumarin-type compound is represented by formula (I), wherein an A ring is independently selected from a group consisting of phenyl, naphthyl, and a 5- to 14-membered aromatic heterocyclic group. The 8-(pyridine triazole) substituted coumarin-type compound of the present application is of a new compound structure, shows good SIRT2 inhibitory activity, and has a remarkable protection effect on neuroma cells. Therefore, the 8-(pyridine triazole) substituted coumarin-type compound can be widely used for preparing a medication for use in the treatment and/or prevention of diseases or disorders associated with too high SIRT2 activity or SIRT2 overexpression, or preparing a medication for use in the treatment and/or prevention of Parkinson's disease, metabolic diseases, and tumors.

Description

A kind of 8-(pyridine triazole) substituted coumarin compound and its preparation method and application

technical field

The application belongs to the technical field of medicine, in particular to a kind of 8-(pyridine triazole) substituted coumarin compound and its preparation method and application, in particular to a kind of compound capable of inhibiting the activity or expression of Sirtuin 2 (also known as SIRT2) 8-(Pyridine triazole) substituted coumarin compounds and preparation method and application thereof.

Background technique

Parkinson's disease is a common neurodegenerative disease, and its main clinical manifestations are slowness of movement, muscle rigidity and resting tremor. The pathological changes of Parkinson's disease are mainly reflected in the degeneration and necrosis of dopaminergic neurons in the substantia nigra of the midbrain, resulting in a significant decrease in the content of dopamine in the striatum. People with Parkinson's disease suffer a heavy burden both physically and psychologically. However, there is currently no drug that can protect the degeneration of nerve cells in Parkinson's disease. The treatment drugs for Parkinson's disease (such as levodopa) on the market are mainly aimed at relieving the symptoms of the disease, and long-term use of such drugs brings serious side effects to patients. Therefore, it is of great significance to explore new treatments for Parkinson's disease and discover new drugs for Parkinson's disease.

As an important member of the Sirtuin family, SIRT2 is mainly distributed in the cytoplasm, and its substrate proteins include α-tubulin, histone H4, p53, FOXO and 14-3-3 protein. Functional studies of SIRT2 show that: SIRT2 regulates the process of cell mitosis by deacetylating H4-K16; SIRT2 maintains genome stability by activating the activity of the Anaphase Promoting Complex/Cyclosome (APC/C) system ; SIRT2 mediates the interaction of Receptor-interacting proteins 1 and 3 (RIP1 and RIP3) to regulate the process of cell necrosis.

The latest research shows that: inhibiting the activity of SIRT2 has potential value in the treatment of Parkinson's disease, which is embodied in: (1) SIRT2 is highly expressed in the central nervous system of the adult brain and regulates related physiological metabolism; (2) SIRT2 siRNA and the small molecule inhibitor AGK2 can rescue the neurotoxicity caused by α-synulein, and AGK2 can also protect neurons from apoptosis in a transgenic Drosophila model of Parkinson's disease in a dose-dependent manner in vivo; (3) SIRT2 is deacetylated by deacetylation FOXO3a increases the expression of Bim at the RNA and protein levels, promoting N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine, MPTP)-induced apoptosis in a Parkinson's disease cell model and in the brain of a MPTP-induced mouse model. However, the brains of mice knocked out of the SIRT2 gene showed significantly reduced nigrostriatal damage; (4) In addition, the small molecule inhibitor of SIRT2, AK-7, was able to significantly reduce another neurodegenerative disease- The accumulation of mutant Huntingtin in the brains of Huntington's disease transgenic mice can significantly improve the behavioral performance and prolong survival time of Huntington's disease transgenic mice.

Representative SIRT2 small molecule inhibitors in the prior art include the following:

However, the types of SIRT2 inhibitors known in the prior art are still very limited. In view of the potential activity of SIRT2 small molecule inhibitors in the treatment of Parkinson's disease, it is very meaningful to design and synthesize new SIRT2 inhibitors.

SUMMARY OF THE INVENTION

In view of the deficiencies in the prior art, the purpose of this application is to provide a kind of 8-(pyridine triazole) substituted coumarin compound and its preparation method and application, especially a kind of 8-( Pyridine triazole) substituted coumarin compound and its preparation method and application. This application has developed a new class of 8-(pyridinetriazole) substituted coumarin compounds with significant SIRT2 inhibitory activity and good selectivity for SIRT2, which can be used for Parkinson's disease, metabolic Prevention and treatment of diseases, tumors, etc.

In order to achieve the purpose of this application, the application adopts the following technical solutions:

In the first aspect, the present application provides an 8-(pyridine triazole) substituted coumarin compound, and the structure of the 8-(pyridine triazole) substituted coumarin compound is shown in formula (I):

wherein the A ring is independently selected from the group consisting of phenyl, naphthyl and 5-14 membered aromatic heterocyclyl (eg 5 membered aromatic heterocyclyl, 6 membered aromatic heterocyclyl, 7 membered aromatic heterocyclyl, 8-membered aromatic heterocyclic group, 9-membered aromatic heterocyclic group, 10-membered aromatic heterocyclic group, 11-membered aromatic heterocyclic group, 12-membered aromatic heterocyclic group, 13-membered aromatic heterocyclic group, 14-membered aromatic heterocyclic group);

The phenyl, naphthyl and 5-14-membered aromatic heterocyclic groups are unsubstituted or substituted with 1-5 (

eg

1, 2, 3, 4, 5) R _a ; R _a is each independently is selected from the group consisting of: deuterium, halogen, hydroxyl, sulfhydryl, amino, cyano, nitro, azido, mesyl, isopropylsulfonyl, benzenesulfonyl, aminosulfonyl, mesylate, Isopropanesulfonate, benzenesulfonate, trifluoromethyl, trifluoromethyloxy, formamido, C _1-8 alkyloxy, C _1-8 alkylcarbonyl, C _1-8 Alkyloxycarbonyl, C _1-8 alkyl, C _3-8 cycloalkyl and phenyl;

In the R _a , the C _1-8 alkyl, C _3-8 cycloalkyl and phenyl are unsubstituted or replaced by 1-5 (

eg

1, 2, 3, 4, 5 _{) R substituted; said R b} _is each independently selected from the group consisting of: deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azido, mesyl, isopropylsulfonyl, benzenesulfonyl Acyl, aminosulfonyl, mesylate, isopropanesulfonate, benzenesulfonate, trifluoromethyl, trifluoromethyloxy, formamido and C _1-8 alkylcarbonyl.

The above C _1-8 refers to the number of carbon atoms of the substituent group is 1, 2, 3, 4, 5, 6, 7, 8; C _3-8 refers to the number of carbon atoms of the

substituent group

3, 4, 5, 6, 7, 8.

The 8-(pyridinetriazole) substituted coumarin compounds involved in this application are a brand-new compound structure, and their in vitro SIRT2 inhibitory activity reaches more than 50%, of which 18 compounds have an in vitro SIRT2 inhibitory activity IC ₅₀ of The micromolar level, especially the IC ₅₀ value of 10 compounds reached the level of 10 ^-7 mol/L, and the IC ₅₀ value of 4 compounds reached the level of 10 ^-8 mol/L, showing good SIRT2 inhibitory activity, and was effective against SIRT2. Neuroma cells have a significant protective effect. Therefore, it can be widely used in the preparation of medicaments for the treatment and/or prevention of diseases or conditions related to the overactivity of SIRT2 or the overexpression of SIRT2 or the preparation of medicines for the treatment and/or prevention of Parkinson's disease, metabolic disease, tumor drug.

Preferably, in formula (I), ring A is independently selected from the group consisting of phenyl, naphthyl and 5-14 membered aromatic heterocyclyl (eg 5 membered aromatic heterocyclyl, 6 membered aromatic heterocyclyl, 7-membered aromatic heterocyclic group, 8-membered aromatic heterocyclic group, 9-membered aromatic heterocyclic group, 10-membered aromatic heterocyclic group, 11-membered aromatic heterocyclic group, 12-membered aromatic heterocyclic group, 13-membered aromatic heterocyclic group, 14-membered aromatic heterocyclic group membered aromatic heterocyclic group);

eg

1, 2, 3, 4, 5) R _a ; R _a is each independently is selected from the group consisting of: deuterium, halogen, hydroxyl, sulfhydryl, amino, cyano, nitro, azido, mesyl, isopropylsulfonyl, benzenesulfonyl, aminosulfonyl, mesylate, Isopropanesulfonate, benzenesulfonate, trifluoromethyl, trifluoromethyloxy, formamido, C _1-6 alkyloxy, C _1-6 alkylcarbonyl, C _1-6 Alkyloxycarbonyl, C _1-6 alkyl, C _3-6 cycloalkyl and phenyl;

In the R _a , the C _1-6 alkyl, C _3-6 cycloalkyl and phenyl are unsubstituted or replaced by 1-5 (

eg

1, 2, 3, 4, 5 _{) R substituted; said R b} _is each independently selected from the group consisting of: deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azido, mesyl, isopropylsulfonyl, benzenesulfonyl Acyl, aminosulfonyl, mesylate, isopropanesulfonate, benzenesulfonate, trifluoromethyl, trifluoromethyloxy, formamido and C _1-6 alkylcarbonyl.

The above-mentioned C _1-6 means that the number of carbon atoms of the substituent is 1, 2, 3, 4, 5 and 6; C _3-6 means that the number of carbon atoms of the substituent is 3 or 4 , 5, 6.

Preferably, the structure of the 8-(pyridine triazole) substituted coumarin compound is shown in formula (IA):

wherein R ₁ , R ₂ , R ₃ , R ₄ and R ₅ are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azide, methanesulfonyl, Isopropanesulfonyl, benzenesulfonyl, aminosulfonyl, mesylate, isopropanesulfonate, benzenesulfonate, trifluoromethyl, trifluoromethyloxy, formamido, C _{1 -4} alkyloxy, C _1-4 alkylcarbonyl, C _1-4 alkyloxycarbonyl, C _1-4 alkyl and phenyl.

The above-mentioned C _1-4 means that the number of carbon atoms of the substituent is 1, 2, 3 or 4.

Preferably, the structure of the 8-(pyridinetriazole) substituted coumarin compound is shown in formula (IB):

wherein R ₁ , R ₂ , R ₃ , R ₄ and R ₅ are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, mesyl, trifluoromethyl , trifluoromethyloxy, formamido, C _1-4 alkyloxy, C _1-4 alkylcarbonyl and C _1-4 alkyl; X is independently selected from N or C.

Further preferably, the 8-(pyridinetriazole) substituted coumarin compound is selected from the following structures (represented by structural formula or system name respectively):

In a second aspect, the present application provides the stereoisomer of the 8-(pyridinetriazole) substituted coumarin compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same as described in the first aspect;

Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable pharmaceutical excipients, such as carriers, diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, Solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, bacteriostatic agents or buffers, etc.

The pharmaceutically acceptable salts of 8-(pyridinetriazole) substituted coumarin compounds involved in the present application are salts formed by 8-(pyridinetriazole) substituted coumarin compounds and an acid selected from the following group: : Hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, tartaric acid, maleic acid, lactic acid, methanesulfonic acid, sulfuric acid, phosphoric acid, citric acid, acetic acid or trifluoroacetic acid. Preferred are hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid or trifluoroacetic acid.

In the third aspect, the present application provides the preparation method of the 8-(pyridinetriazole) substituted coumarin compound as described in the first aspect, the preparation method comprising:

Will

Mix with 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)picolinic acid, and react to obtain; wherein, A ring The limited scope is consistent with the limited scope of the first aspect;

Its reaction formula is as follows:

Preferably, the preparation method of 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)picolinic acid comprises the following steps:

(1) ₈ -bromocoumarin and NaN are mixed, react, obtain 8-azidocoumarin;

(2) Mix 8-azidocoumarin with 3-ethynylpicolinic acid and cuprous iodide, and react to obtain 3-(1-(2-oxo-2H-chromen-8-yl)- 1H-1,2,3-triazol-4-yl)picolinic acid;

Its reaction formula is as follows:

The preparation method of the 8-(pyridinetriazole) substituted coumarin compound involved in the present application is simple and easy to operate, suitable for industrial production, and practical.

As the preferred technical solution of the present application, the preparation method of the 8-(pyridinetriazole) substituted coumarin compound comprises the following steps:

(1) NaN ₃ was added to the ultra-dry DMF solution of 8-bromocoumarin at room temperature. The reaction solution was heated at 40°C. TLC detected that the reaction was complete, and the reaction solution was cooled to room temperature and quenched with saturated brine. The product was extracted three times with dichloromethane. The combined organic phases were dried with anhydrous sodium sulfate, filtered, and the solvent was evaporated, and the product was 8-azidocoumarin after purification on a silica gel column.

(2) 8-Azidocoumarin, 3-ethynylpicolinic acid, cuprous iodide were added to ultra-dry dichloromethane and the reaction was stirred at room temperature. After the completion of the reaction was detected by TLC, the product was purified by silica gel column to obtain 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)pyridine formic acid.

(3) Add 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)picolinic acid and condensing agent HATU to the single-necked bottle , various amines, DIPEA, ultra-dry dichloromethane. Stir at room temperature. The reaction was complete as detected by TLC. Water was added to the mixture, extracted three times with ethyl acetate, washed with saturated brine, and dried over anhydrous sodium sulfate. The product was obtained by silica gel column purification.

In a fourth aspect, the present application provides an 8-(pyridinetriazole) substituted coumarin compound as described in the first aspect or an 8-(pyridinetriazole) substituted coumarin as described in the second aspect Stereoisomers of class compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them in the manufacture of a medicament for the treatment and/or prevention of diseases or conditions associated with excessive SIRT2 activity or overexpression of SIRT2 application.

Preferably, the disease or condition associated with excessive SIRT2 activity or SIRT2 overexpression includes Parkinson's disease, metabolic disease or tumor.

In the fifth aspect, the present application also provides an 8-(pyridinetriazole) substituted coumarin compound as described in the first aspect or an 8-(pyridinetriazole) substituted coumarin as described in the second aspect Stereoisomers of prime compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them in the preparation of SIRT2 inhibitors.

In a sixth aspect, the application also provides a method for treating and/or preventing a disease or condition related to SIRT2 overactivity or overexpression of SIRT2, the method comprising: treating and/or preventing a subject in need thereof Stereoisomerism of an effective amount of the 8-(pyridinetriazole) substituted coumarin compounds described in the first aspect or the 8-(pyridinetriazole) substituted coumarin compounds described in the second aspect body, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

Various aspects and features of the present application are further described below.

The various terms and phrases used in this application have the general meanings known to those skilled in the art. Even so, the application still hopes to make more detailed descriptions and explanations for these terms and phrases. If the known meanings are inconsistent, the meanings expressed in this application shall prevail. The following are definitions of various terms used in this application, and these definitions apply to the terms used throughout the specification of this application unless otherwise indicated in a specific case. Definitions of various groups of the compounds of the present application are provided below, and unless otherwise defined, they are used uniformly in the specification and claims.

As referred to in this application, the terms "halo", "halogen", "halogen atom", "halo" and the like mean fluorine, chlorine, bromine or iodine, especially fluorine, chlorine or bromine.

As referred to in this application, the term "alkyl" refers to an alkyl group having the specified number of carbon atoms, which may be a straight-chain or branched-chain alkyl group, such as the "C _1-8 alkyl group" mentioned. , refers to alkyl groups with carbon atoms of 1, 2, 3, 4, 5, 6, 7, and 8, which may include C _1-8 alkyl, C _1-7 alkyl, C _2-8 alkyl, C _2-7 alkyl, C _2-6 alkyl, C _3-8 alkyl, C _3-7 alkyl, C _3-6 alkyl, etc. represent sub-range groups, and preferred specific groups such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec-butyl group, tert-butyl group, pentyl group, hexyl group, heptyl group, octyl group, more preferably methyl group and isopropyl group. For example, "C _1-6 alkyloxy", "C _1-6 alkyl formyl", "C _1-6 alkyloxyformyl" or "C _1-6 alkyl" in "C 1-6 alkyl"" _1-6 alkyl" refers to an alkyl group with 1, 2, 3, 4, 5, and 6 carbon atoms, which may include C _1-5 alkyl, C _1-4 alkyl, and C _2-6 alkyl , C _2-5 alkyl, C _2-4 alkyl, C _3-6 alkyl, C _3-5 alkyl, C _3-4 alkyl, etc. represented by sub-range groups, and preferred specific groups For example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, and more preferably methyl. For example, the "C _1-4 alkyl group" in the "C _1-4 alkylcarbonyl group" or "C _1-4 alkyloxycarbonyl group" refers to an alkane having 1, 2, 3, or 4 carbon atoms. radicals, which may include sub-range groups represented by C _1-4 alkyl, C _2-4 alkyl, etc., as well as preferred specific groups such as methyl, ethyl, n-propyl, isopropyl.

As referred to in this application, the term "cycloalkyl" refers to a cyclic alkyl group having the specified number of ring carbon atoms, for example, when referring to "C3-8 cycloalkyl", it refers to 3 carbon atoms , 4, 5, 6, 7, and 8 cycloalkyl groups, may include groups in the sub-ranges represented by C3-7 cycloalkyl, C3-4 cycloalkyl, C4-6 cycloalkyl, etc., and preferred specific Groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, more preferably cyclopropyl, cyclopentyl, cyclohexyl. For example, the "C3-6 cycloalkyl" refers to a cycloalkyl group with 3, 4, 5, and 6 carbon atoms, which may include C3-6 cycloalkyl, C3-5 cycloalkyl, C4-5 Sub-range groups represented by cycloalkyl, etc., and preferred specific groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, more preferably cyclopropyl, cyclopentyl, cyclohexyl .

As referred to herein, the term "aromatic heterocyclyl" refers to a heterocyclic aromatic system containing from 1 to 4 heteroatoms, including nitrogen, oxygen and sulfur heteroatoms. As referred to in this application, "5-14 membered aromatic heterocyclyl" refers to a heterocyclic aromatic system containing 5-14 ring atoms. Specific examples include aryl groups containing 1 carbon atom and 4 heteroatoms selected from nitrogen, oxygen and sulfur, preferred specific groups such as tetrazolyl; containing 2 carbon atoms and 3 heteroatoms selected from nitrogen, oxygen , aryl groups of heteroatoms of sulfur, preferred specific groups such as 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl; containing 3 Aryl with carbon atoms and 2 heteroatoms selected from nitrogen, oxygen, sulfur, preferred specific groups such as imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl; containing 4 aryl groups of carbon atoms and 1-2 heteroatoms selected from nitrogen, oxygen, sulfur, preferred specific groups such as pyrrolyl, furanyl, thienyl, pyridazinyl, pyrimidinyl, pyrazinyl; containing 5 an aryl group containing 6 carbon atoms and 1 heteroatom selected from nitrogen, oxygen and sulfur, and a preferred specific group such as pyridyl, preferably pyridyl; containing 6 carbon atoms and 3 heteroatoms selected from nitrogen, oxygen and sulfur aryl groups of atoms, preferred specific groups such as benzotriazolyl; aryl groups containing 7 carbon atoms and 2 heteroatoms selected from nitrogen, oxygen, sulfur, preferred specific groups such as benzimidazolyl, Benzopyrazolyl; Aryl containing 8 carbon atoms and 1-2 heteroatoms selected from nitrogen, oxygen, sulfur, preferred specific groups such as indolyl, benzofuranyl, benzothienyl, Benzopyrazinyl, benzopyrimidinyl, benzopyridazinyl; aryl groups containing 9 carbon atoms and 1 heteroatom selected from nitrogen, oxygen, sulfur, preferred specific groups such as quinolinyl, iso Quinolinyl.

As referred to herein, the term "effective amount" refers to a dose that will effect treatment and/or prevention of the disease or disorder described herein in a subject.

As referred to in this application, the term "pharmaceutical composition", which may also refer to a "composition", can be used to effect the treatment and/or prevention of the diseases or conditions described herein in a subject, particularly a mammal .

As referred to in this application, the term "subject" may refer to a patient or other animal receiving a compound, a pharmaceutically acceptable salt or a pharmaceutical composition thereof referred to in this application for the treatment and/or prevention of a disease or disorder described in this application, In particular mammals such as humans, dogs, monkeys, cows, horses and the like.

As referred to herein, the term "disease and/or disorder" refers to a physical condition of the subject that is associated with the disease and/or disorder described herein. For example, the disease and/or disorder described in this application can refer to either a physical state, such as a physical state of Parkinson's disease, or a disease state, such as a disease state of Parkinson's disease. No distinction is made herein between a physical state and a disease state, or the two may refer to each other, eg, "Parkinson's disease" and "Parkinson's disease" are used interchangeably.

As referred to in this application, the term "pharmaceutically acceptable", eg, when describing a "pharmaceutically acceptable salt", means that the salt is not only physiologically acceptable to the subject, but can also refer to a pharmaceutically acceptable salt. Synthetic substances of use value, such as salts formed as intermediates for chiral resolution, although the salts of such intermediates cannot be administered directly to the subject, the salts can be used in order to obtain the final product of the present application. function in.

Yet another aspect of the present application also relates to pharmaceutical compositions containing the compounds of the present application as active ingredients. The pharmaceutical composition can be prepared according to methods known in the art. Any dosage form suitable for human or animal use can be prepared by combining the compounds of the present application with one or more pharmaceutically acceptable solid or liquid excipients and/or adjuvants. The content of the compound of the present application in its pharmaceutical composition is usually 0.1-95% by weight.

The compound of the present application or the pharmaceutical composition containing it can be administered in unit dosage form, and the route of administration can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal cavity, oral mucosa, eye, lung and Respiratory tract, skin, vagina, rectum, etc.

The dosage form for administration can be a liquid dosage form, a solid dosage form or a semi-solid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o/w, w/o and double emulsion), suspensions, injections (including water injection, powder injection and infusion), eye drops solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, buccal tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules ( Including hard capsules, soft capsules, enteric-coated capsules), granules, powders, pellets, drop pills, suppositories, films, patches, gas (powder) aerosols, sprays, etc.; semi-solid dosage forms can be ointments, Gels, pastes, etc.

The compounds of the present application can be prepared into ordinary preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.

In order to formulate the compounds of the present application into tablets, various excipients well known in the art can be widely used, including diluents, binders, wetting agents, disintegrating agents, lubricants, and cosolvents. The diluent can be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; Propanol, etc.; the binder can be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia mucilage, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methylcellulose Base cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinylpyrrolidone, polyethylene glycol, etc.; disintegrants can be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polymer Vinylpyrrolidone, croscarmellose sodium, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfonate, etc.; lubricants and cosolvents It can be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol and the like.

The tablets can also be further prepared as coated tablets, such as sugar-coated, film-coated, enteric-coated, or bilayer and multi-layer tablets.

In order to make the dosage unit into a capsule, the active ingredient of the compound of the present application can be mixed with a diluent and a cosolvent, and the mixture can be directly placed in a hard capsule or a soft capsule. The compound of the present application, the active ingredient, can also be prepared into granules or pellets with diluents, binders and disintegrating agents, and then placed in hard capsules or soft capsules. The various diluents, binders, wetting agents, disintegrants, and cosolvents used to prepare tablets of the compounds of the present application can also be used to prepare capsules of the compounds of the present application.

To prepare the compounds of the present application into injections, water, ethanol, isopropanol, propylene glycol or their mixtures can be used as solvents and appropriate amount of solubilizers, cosolvents, pH regulators and osmotic pressure regulators commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure adjuster can be It is sodium chloride, mannitol, glucose, phosphate, acetate, etc. For example, in the preparation of freeze-dried powder injection, mannitol, glucose, etc. can also be added as proppant.

In addition, colorants, preservatives, fragrances, flavors, or other additives can also be added to the pharmaceutical preparations, if desired.

In order to achieve the purpose of medication and enhance the therapeutic effect, the medicine or pharmaceutical composition of the present application can be administered by any known administration method.

The dosage of the pharmaceutical composition of the compound of the present application can vary widely according to the nature and severity of the disease to be prevented or treated, the individual condition of the patient or animal, the route of administration and the dosage form. In general, the suitable daily dosage range of the compounds involved in this application is 0.001-150 mg/kg body weight, preferably 0.1-100 mg/kg body weight, more preferably 1-60 mg/kg body weight, most preferably 2-30 mg/kg body weight weight. The above doses may be administered in a single dosage unit or divided into several dosage units, depending on the clinical experience of the physician and the dosing regimen including the use of other therapeutic means.

The compounds or compositions of the present application may be administered alone or in combination with other therapeutic or symptomatic drugs. When the compound of the present application has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.

Compared with the prior art, the present application has the following beneficial effects:

Description of drawings

FIG. 1 is a statistical graph of the protective effect of the 8-(pyridinetriazole) substituted coumarin compounds involved in the present application on SH-SY5Y cell damage in Test Example 3. FIG.

Detailed ways

The technical solutions of the present application are further described below through specific embodiments. It should be understood by those skilled in the art that the embodiments are only for helping the understanding of the present application, and should not be regarded as a specific limitation of the present application.

For all of the following examples or preparations, standard procedures and purification methods known to those skilled in the art can be used. Unless otherwise stated, all temperatures are expressed in °C (Celsius) and the structures of compounds were determined by nuclear magnetic resonance spectroscopy (NMR) and/or mass spectrometry (MS).

For all of the following examples or preparations, the structures of the compounds were determined by hydrogen nuclear magnetic resonance spectroscopy ( ¹ H NMR) or mass spectrometry (MS). H NMR spectral shifts (δ) are given in parts per million (ppm). The nuclear magnetic resonance spectrum was measured with Mercury-300 or Mercury-400 nuclear magnetic resonance apparatus, deuterated chloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-d6) as solvent, tetramethylsilane (TMS) or 3-( Trimethylsilyl) sodium deuterated propionate (TSM) was used as the internal standard.

The electronic balance adopts Japanese Yanaco LY-300 electronic balance.

Column chromatography uses 200-300 mesh or 300-400 mesh silica gel as a carrier.

Anhydrous solvents were all worked up by standard methods. All other reagents were of commercially available analytical grade.

in,

HATU is 2-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluor-ophosphat, namely 2-(7-azabenzotriazole)-N,N,N' , N'-tetramethylurea hexafluorophosphate.

DIPEA is N,N-diisomromylethylamine, namely N,N-diisopropylethylamine.

DMF is N,N-dimethylformamide, that is, N,N-dimethylformamide.

The sources of the raw materials involved in the following preparations and examples are as follows:

8-Bromocoumarin was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., CAS: 33491-30-4;

3-Ethynylpicolinic acid was purchased from Shanghai Hanhong Technology Co., Ltd.;

Purchased from Shanghai McLean Biochemical Technology Co., Ltd., Sigma-Aldrich (Shanghai) Trading Co., Ltd., Beijing Bailingwei Technology Co., Ltd., Shanghai Merrill Chemical Technology Co., Ltd., and Alfa Aesar (China) Chemical Co., Ltd. , Beijing Coupling Technology Co., Ltd., Shanghai Aladdin Biochemical Technology Co., Ltd., Beijing Solebao Technology Co., Ltd., Beijing Inoke Technology Co., Ltd.

Preparation Example 1

This preparation example prepares the intermediate 3 shown in the following formula, and the synthetic route is:

(1) To an ultra-dry DMF solution (15 mL) of 8-bromocoumarin (5.00 g, 22.33 mmol) at 20°C was added NaN ₃ (1.74 g, 26.80 mmol). The reaction solution was heated at 40°C for 14 hours. TLC detected that the reaction was complete, and the reaction solution was cooled to 20°C and quenched with saturated brine. The product was extracted three times with dichloromethane (20 mL x 3). The combined organic phases were dried with anhydrous sodium sulfate, filtered, and the solvent was evaporated to obtain the product 8-azidocoumarin (1.42 g, yield 37%) by silica gel column purification.

(2) 8-Azidocoumarin (1.30 g, 6.95 mmol), 3-ethynylpicolinic acid (1.02 g, 6.95 mmol) and cuprous iodide (0.13 g, 0.70 mmol) were added to the ultra-dry two Chloromethane (15 mL), and the reaction was stirred at 20 °C for 25 min. After the completion of the reaction was detected by TLC, the product was purified by silica gel column to obtain 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)pyridine Formic acid (2.04 g, 88% yield).

Example 1

Compound 1 prepared in this example: N-(2-(4-chlorobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3-tri azol-4-yl) pyridine amide, the structure of which is shown below:

Add 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)picolinic acid (1.67g, 5.00mmol) to a single-necked flask , the condensing agent HATU (2.28g, 6.00mmol),

(5.00 mmol), DIPEA (1.74 mL, 10.00 mmol), ultra-dry dichloromethane (15 mL). Stir at 20°C for 5 hours. The reaction was complete as detected by TLC. Water was added to the mixture, extracted three times with ethyl acetate (15 mL×3), washed with saturated brine, and dried over anhydrous sodium sulfate. Purified by silica gel column to obtain 0.32 g of white solid with a yield of 14%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl ₃ ): δ 8.69 (d, J=5.2Hz, 1H), 8.44 (d, J=4.5Hz, 1H), 8.10 (s, 1H), 7.65-7.93 (m, 4H) ),7.30-7.50(m,5H),6.25(m,1H),4.11(s,2H).

HR-MS (ESI): [M+H]+Calcd for C ₂₄ H ₁₇ ClN ₅ O ₃ 458.1020, found 458.1055.

Example 2

Compound 2 prepared in this example: N-(2-(3-chlorobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3-tri azol-4-yl) pyridine amide, the structure of which is shown below:

The preparation was carried out with reference to the preparation method in Example 1, and the raw materials were

replace with

0.44 g of white solid was obtained with a yield of 19%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl3): δ 8.67 (d, J=5.2Hz, 1H), 8.54 (d, J=4.3Hz, 1H), 8.08 (s, 1H), 7.71-7.97 (m, 4H) ,7.30-7.48(m,4H),7.11(m,1H),6.25(m,1H),4.14(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₄ H ₁₇ ClN ₅ O ₃ 458.1020, found 458.1035.

Example 3

Compound 3 prepared in this example: N-(2-(2-chlorobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3-tri azol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.48 g of white solid was obtained with a yield of 20%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl3): δ8.67 (d, J=5.2Hz, 1H), 8.47 (d, J=4.3Hz, 1H), 8.10 (s, 1H), 7.67-7.95 (m, 5H) ,7.20-7.41(m,3H),7.17(m,1H),6.25(m,1H),4.23(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₄ H ₁₇ ClN ₅ O ₃ 458.1020, found 458.1041.

Example 4

Compound 4 prepared in this example: N-(2-(4-methylbenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3- Triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.55 g of white solid was obtained with a yield of 25%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl ₃ ): δ 8.69 (d, J=5.2Hz, 1H), 8.44 (d, J=4.5Hz, 1H), 8.10 (s, 1H), 7.65-7.93 (m, 4H) ), 7.42(m, 1H), 7.11(m, 4H), 6.25(m, 1H), 4.11(s, 2H), 2.34(s, 3H).

HR-MS(ESI): [M+H]+Calcd for C ₂₅ H ₂₀ N ₅ O ₃ 438.1566, found 438.1578.

Example 5

Compound 5 prepared in this example: N-(2-(3-nitrobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3- Triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.75 g of white solid was obtained with a yield of 32%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl ₃ ): δ 8.69 (d, J=5.2Hz, 1H), 8.44 (d, J=4.5Hz, 1H), 8.08-8.10 (m, 3H), 7.65-7.97 (m ,6H),7.42(m,1H),6.25(m,1H),4.11(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₄ H ₁₇ N ₆ O ₅ 469.1260, found 469.1276.

Example 6

Compound 6 prepared in this example: N-(2-(2-cyanobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3- Triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.63 g of white solid was obtained with a yield of 28%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl ₃ ): δ 8.67 (d, J=5.2Hz, 1H), 8.42 (d, J=4.5Hz, 1H), 8.08 (m, 1H), 7.65-7.97 (m, 4H) ),7.42-7.60(m,5H),6.25(m,1H),4.23(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₅ H ₁₇ N ₆ O ₃ 449.1362, found 449.1377.

Example 7

Compound 7 prepared in this example: N-(2-(4-fluorobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3-tri azol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.68 g of white solid was obtained with a yield of 31%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.69 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.10 (s, 1H), 7.65-7.93 (m, 4H) ),7.34-7.56(m,5H),6.25(m,1H),4.11(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₄ H ₁₇ FN ₅ O ₃ 442.1315, found 442.1334.

Example 8

Compound 8 prepared in this example: N-(2-(4-methanesulfonylbenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3 - Triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.53 g of white solid was obtained with a yield of 21%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.67 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.10 (s, 1H), 7.51-7.93 (m, 8H) ),7.42(m,1H),6.25(m,1H),4.11(s,2H),3.32(s,3H).

HR-MS(ESI): [M+H]+C ₂₅ H ₂₀ N ₅ O ₅ S calcd. 502.1185, found 502.1197.

Example 9

Compound 9 was prepared in this example: N-(2-(4-trifluoromethylbenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2, 3-Triazol-4-yl) pyridine amide, its structure is shown below:

replace with

0.88 g of white solid was obtained with a yield of 36%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.69 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.09 (s, 1H), 7.65-7.97 (m, 4H) ), 7.50(d, J=5.5Hz, 2H), 7.14(d, J=5.7Hz, 2H), 6.25(m, 1H), 4.13(s, 2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₅ H ₁₇ F ₃ N ₅ O ₃ 492.1283, found 492.1299.

Example 10

Compound 10 prepared in this example: N-(2-(4-phenylbenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3- Triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.57 g of white solid was obtained with a yield of 23%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.69 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.09 (s, 1H), 7.64-7.98 (m, 4H) ),7.51-7.53(m,4H),7.29-7.44(m,6H),6.25(m,1H),4.13(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₃₀ H ₂₂ N ₅ O ₃ 500.1723, found 500.1747.

Example 11

Compound 11 prepared in this example: N-(2-(4-hydroxybenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3-tri azol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.52 g of white solid was obtained with a yield of 24%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.68 (d, J=5.0 Hz, 1H), 8.42 (d, J=4.4 Hz, 1H), 8.09 (s, 1H), 7.65-7.97 (m, 4H) ),7.42(m,1H),7.18(m,2H),6.78(m,2H),6.25(m,1H),4.13(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₄ H ₁₈ N ₅ O ₄ 440.1359, found 440.1377.

Example 12

Compound 12 prepared in this example: N-(2-(4-methoxybenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2,3- Triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.59 g of white solid was obtained with a yield of 26%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.68 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.09 (s, 1H), 7.61-7.95 (m, 4H) ),7.42(m,1H),7.25(m,2H),6.87(m,2H),6.25(m,1H),4.11(s,2H),3.83(s,3H).

HR-MS(ESI): [M+H]+Calcd for C ₂₅ H ₂₀ N ₅ O ₄ 454.1515, found 454.1567.

Example 13

Compound 13 was prepared in this example: N-(2-(3,4-difluorobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2, 3-Triazol-4-yl) pyridine amide, its structure is shown below:

replace with

0.48 g of white solid was obtained with a yield of 21%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.68 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.4 Hz, 1H), 8.10 (s, 1H), 7.67-7.97 (m, 4H) ),7.42(m,1H),6.89-7.12(m,3H),6.25(m,1H),4.11(s,2H).

HR-MS(ESI): [M+H]+C ₂₄ H ₁₆ F ₂ N ₅ O ₃ calcd. 460.1221, found 460.1253.

Example 14

Compound 14 prepared in this example: N-(2-(3-bromo-4-chlorobenzyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1,2 , 3-triazol-4-yl) pyridine amide, its structure is as follows:

replace with

0.37 g of white solid was obtained with a yield of 14%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.68 (d, J=5.2 Hz, 1H), 8.44 (d, J=4.2 Hz, 1H), 8.09 (s, 1H), 7.67-7.97 (m, 4H) ),7.26-7.42(m,4H),6.25(m,1H),4.11(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₄ H ₁₆ BrClN ₅ O ₃ 536.0125, found 536.0147.

Example 15

Compound 15 prepared in this example: N-(2-((7-bromoner-1-yl)methyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H -1,2,3-Triazol-4-yl)pyridineamide, the structure of which is shown below:

replace with

0.49 g of white solid was obtained with a yield of 18%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.68 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.2 Hz, 1H), 8.28 (s, 1H), 8.08 (s, 1H), 7.67-7.97(m,7H),7.42-7.47(m,2H),7.07(m,1H),6.25(m,1H),4.67(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₈ H ₁₉ BrN ₅ O ₃ 552.0671, found 552.0698.

Example 16

Compound 16 prepared in this example: N-(2-((3-chloronaphthalen-1-yl)methyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H -1,2,3-Triazol-4-yl)pyridineamide, the structure of which is shown below:

replace with

0.27 g of white solid was obtained with a yield of 11%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.68 (d, J=5.0 Hz, 1H), 8.44 (d, J=4.0 Hz, 1H), 8.18 (s, 1H), 8.05-8.08 (m, 2H) ),7.67-7.97(m,4H),7.42-7.54(m,4H),7.11(m,1H),6.25(m,1H),4.67(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₈ H ₁₉ ClN ₅ O ₃ 508.1176, found 508.1192.

Example 17

Compound 17 prepared in this example: N-(2-((quinolin-5-yl)methyl)-3-(1-(2-oxo-2H-chromogen-8-yl)-1H-1 , 2,3-triazol-4-yl) pyridine amide, the structure of which is shown below:

replace with

0.38 g of white solid was obtained with a yield of 16%. The product was characterized as follows:

¹ H NMR (400 MHz, CDCl ₃ ): δ 8.40-8.80 (m, 4H), 8.08 (m, 1H), 7.67-7.97 (m, 6H), 7.42-7.57 (m, 3H), 6.25 (m, 1H), 4.23(s, 2H).

HR-MS(ESI): [M+H]+C ₂₇ H ₁₉ N ₆ O ₃ calcd. 475.1519, found 475.1542.

Example 18

Compound 18 prepared in this example: N-(2-((7-Bromo-quinolin-5-yl)methyl)-3-(1-(2-oxo-2H-chromen-8-yl) -1H-1,2,3-Triazol-4-yl)pyridineamide, the structure of which is shown below:

replace with

0.38 g of white solid was obtained with a yield of 14%. The product was characterized as follows:

¹ H NMR (400MHz, CDCl ₃ ): δ 8.45-8.92 (m, 4H), 8.08 (m, 1H), 7.56-7.97 (m, 7H), 7.42 (m, 1H), 6.25 (m, 1H) ,4.23(s,2H).

HR-MS(ESI): [M+H]+Calcd for C ₂₇ H ₁₈ BrN ₆ O ₃ 553.0624, found 553.0657.

Test Example 1

In vitro activity screening of SIRT2 inhibitors:

The ORF of the full-length expressed sequence of human SIRT2 gene is 1170bp (Accession No.: NM_012237), and the size of the expressed SIRT2 protein is 43KDa. The expression and purification steps of the SIRT2 recombinant protein are as follows: the SIRT2 gene is cloned into the expression vector pET-15b (primers are as follows: Forward: 5'-TAATACGACTCACTATAGGG-3' (SEQ ID NO. 1); backward: 5'-TTCACTTCTGAGTTCGGCATG-3' (SEQ ID NO. 1) ID NO. 2)), the expressed SIRT2 protein contains the tag His ₆ at the N-terminus for purification. Plasmids were transformed into E. coli BL2 (DE3), induced with 1 mM IPTG, and expressed for 6 hours at 18°C. The induced E. coli cells were collected by centrifugation and frozen at -20°C. The bacterial pellet was resuspended in 15 mL of cell lysate (50 mM Tris-HCl pH 8.0, 300 mM NaCl), and the bacterial sample was sonicated for 10 min, and then centrifuged at 4°C (12000×g, 20 min) to remove the pellet. Recombinantly expressed soluble SIRT2 protein was present in the supernatant. The supernatant was purified through a Ni ²⁺ NTA-agarose matrix column (Qiagen). In the purification process, the unbound proteins were first washed with the loading solution (50mM Tris-HCl pH 8.0, 300mM NaCl), and then the concentration of imidazole (0-200mM) was gradually increased to wash away the non-specifically bound proteins, and finally the obtained Purified recombinant SIRT2 protein. The imidazole was removed using a PD-10 column, and the concentration of purified SIRT2 protein was determined by the Bradford method. Recombinant SIRT2 protein was stored in storage solution (50 mM Tris-HCl, pH 8.0, 265 mM NaCl, 0.2 mM DTT, and 10% glycerol) at -20°C.

According to the reports in the literature, an assay method for SIRT2 enzyme activity was established. Firstly, the SIRT2 substrate peptide Ac-Gln-Pro-Lys-[Lys-(Ac)]-AMC was synthesized as the substrate in the enzyme activity assay method. The attached fluorescent tag is AMC (7-Amino-4-methylcoumarin). The entire assay process consists of two steps: the catalytic reaction is carried out in 60 μL of reaction solution (25 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl ₂ and 1 mg/ml BSA), 500 μM NAD ⁺ , 50 μM base peptides, 1.0 μg of SIRT2 and different concentrations of compounds 1-18. The reaction was left at 37°C for 2 hours. In this reaction, the acetyl group of the Lysine residue on the small molecule peptide was removed to varying degrees. Then, 60 μL of a sample treatment solution (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, Trypsin and 4 mM nicotinamide) was added to the reaction solution, mixed, and left at 37° C. for 20 minutes. The microplate reader was set to excitation light of 355 nm and absorption light of 460 nm to measure the absorption intensity. Each compound in the experiment has 2 parallel experiments for each concentration, and a reasonable control is set. The experimental results are processed by the software GraphPad Prism to calculate the inhibitory activity IC ₅₀ of each inhibitor. The results are shown in Table 1 (where AGK is the positive control group):

Table 1

From the data in Table 1, it can be seen that the in vitro SIRT2 inhibitory activity IC ₅₀ of the 18 compounds tested all reached the micromolar level, especially the IC ₅₀ value of 10 compounds reached the level of 10 ^-7 mol/L, and 4 of them had The IC ₅₀ value reached the level of 10 ^-8 mol/L, indicating that the 8-(pyridinetriazole) substituted coumarin compounds involved in this application have good SIRT2 inhibitory activity.

Test Example 2

Cytotoxicity assay of compounds on neuroma cell SH-SY5Y:

In this test example, the cytotoxicity of the compound to neuroma cell SH-SY5Y was determined, so as to determine the dosage of the next Parkinson's cell model protection test. For the determination of cytotoxicity, the specific experimental steps are as follows: the cultured neuroma cells SH-SY5Y were seeded in a 96-well cell culture plate, with about 6000 cells per well. After overnight incubation, change to new medium and add different concentrations of compound 1-18 (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 20, 50, 100, 200 μM) to each well, and set different control samples . Cells were incubated at 37°C for an additional 48 hours. Add 10 μL of dye to each well

(Invitrogen) continued to be incubated at 37°C for about 2 hours, the color change of the staining solution could be observed, and the change in absorbance value was read under a microplate reader (Ex: 530 nm; Em: 590 nm). There were 2 replicates for each concentration of compound in the test. The data processing software GraphPad Prism was used to calculate the cytotoxic CC ₅₀ of each compound. The results are shown in Table 2 (where Taxol is the positive control group):

Table 2

From the data in Table 2, it can be seen that the cytotoxic CC50 of the 18 tested compounds to SH-SY5Y is greater than 20 μM, that is, the 8-(pyridinetriazole) substituted coumarin compounds involved in this application are not effective for SH-SY5Y cells. No obvious inhibitory activity.

Test Example 3

Screening for compounds with protective activity in a cellular model of Parkinson's disease:

For the screening test of the protective effect of the Parkinson's disease cell model, the currently generally recognized nerve agent MPP ⁺ (5mM) was used to act on the neuroma cell SH-SY5Y to construct the Parkinson's disease cell model. This nerve agent acts on SH-SY5Y cells to affect the abnormal accumulation of α-synuclein in the cells and causes neurotoxicity similar to Parkinson's disease. The specific experimental method is as follows: about 20,000 SH-SY5Y cells were seeded in a 96-well cell plate and cultured overnight. In the control experiment, no nerve agent was added, the nerve agent MPP ⁺ (5mM) was added to each well of the other groups, and the MPP+ group was an unprotected compound. AGK is a positive control), and continued to culture for 48 hours to determine the cell viability of the Parkinson's disease cell model to evaluate their protective effect on the Parkinson's cell model. GraphPad Prism was used for data analysis of experimental results. The results are shown in Figure 1.

It can be seen from Figure 1 that the 18 compounds tested can protect the damage of MPP ⁺ nerve agent to SH-SY5Y cells to a certain extent, indicating that the 8-(pyridine triazole) substituted coumarin compounds involved in the present application It has a protective effect on neuroma cells; and among them, compounds 1, 2, 9, 13, and 14 have more obvious protective effects on neuroma cells.

The applicant declares that a kind of 8-(pyridinetriazole) substituted coumarin compound of the present application and its preparation method and application are illustrated by the above-mentioned examples, but the present application is not limited to the above-mentioned examples, namely It does not mean that the present application must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement to the application, the equivalent replacement of each raw material of the product of the application, the addition of auxiliary components, the selection of specific methods, etc., all fall within the scope of protection and disclosure of the application.

The preferred embodiments of the present application have been described in detail above. However, the present application is not limited to the specific details of the above-mentioned embodiments. Within the scope of the technical concept of the present application, various simple modifications can be made to the technical solutions of the present application. These simple modifications All belong to the protection scope of this application.

In addition, it should be noted that the specific technical features described in the above-mentioned specific embodiments can be combined in any suitable manner unless they are inconsistent. The combination method will not be specified otherwise.

Claims

A kind of 8-(pyridine triazole) substituted coumarin compound, its structure is shown in formula (I):

wherein, the A ring is independently selected from the group consisting of phenyl, naphthyl and 5-14-membered aromatic heterocyclyl;

The phenyl, naphthyl and 5-14-membered aromatic heterocyclic groups are unsubstituted or substituted by 1-5 R a ; R a is independently selected from the group consisting of: deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azido, methanesulfonyl, isopropylsulfonyl, benzenesulfonyl, sulfamoyl, mesylate, isopropylsulfonate, benzenesulfonate, trifluoromethyl , trifluoromethyloxy, formamido, C 1-8 alkyloxy, C 1-8 alkylcarbonyl, C 1-8 alkyloxycarbonyl, C 1-8 alkyl, C 3-8 ring Alkyl and phenyl;

In the R a , the C 1-8 alkyl, C 3-8 cycloalkyl and phenyl are unsubstituted or substituted by 1-5 R b ; the R b is each independently selected from the group consisting of Group: Deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azido, mesyl, isopropanesulfonyl, benzenesulfonyl, sulfamoyl, mesylate, isopropanesulfonate group, benzenesulfonate group, trifluoromethyl group, trifluoromethyloxy group, formamido group and C 1-8 alkylcarbonyl group.
The 8-(pyridinetriazole) substituted coumarin compound of claim 1, wherein, in formula (I), ring A is independently selected from the group consisting of phenyl, naphthyl and 5-14 Aromatic heterocyclic group;

The phenyl, naphthyl and 5-14-membered aromatic heterocyclic groups are unsubstituted or substituted by 1-5 R a ; R a is independently selected from the group consisting of: deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azido, methanesulfonyl, isopropylsulfonyl, benzenesulfonyl, sulfamoyl, mesylate, isopropylsulfonate, benzenesulfonate, trifluoromethyl , trifluoromethyloxy, formamido, C 1-6 alkyloxy, C 1-6 alkylcarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkyl, C 3-6 ring Alkyl and phenyl;

In the R a , the C 1-6 alkyl, C 3-6 cycloalkyl and phenyl are unsubstituted or substituted by 1-5 R b ; the R b is each independently selected from the group consisting of Group: Deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azido, mesyl, isopropanesulfonyl, benzenesulfonyl, sulfamoyl, mesylate, isopropanesulfonate group, benzenesulfonate group, trifluoromethyl group, trifluoromethyloxy group, formamido group and C 1-6 alkylcarbonyl group.
The 8-(pyridinetriazole) substituted coumarin compound according to claim 1 or 2, wherein the structure of the 8-(pyridinetriazole) substituted coumarin compound is as shown in formula (IA) Show:

wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, azide, methanesulfonyl, Isopropanesulfonyl, benzenesulfonyl, aminosulfonyl, mesylate, isopropanesulfonate, benzenesulfonate, trifluoromethyl, trifluoromethyloxy, formamido, C 1 -4 alkyloxy, C 1-4 alkylcarbonyl, C 1-4 alkyloxycarbonyl, C 1-4 alkyl and phenyl.
The 8-(pyridinetriazole) substituted coumarin compound according to claim 1 or 2, wherein the structure of the 8-(pyridinetriazole) substituted coumarin compound is as shown in formula (IB) Show:

wherein R 1 , R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, amino, cyano, nitro, mesyl, trifluoromethyl , trifluoromethyloxy, formamido, C 1-4 alkyloxy, C 1-4 alkylcarbonyl and C 1-4 alkyl; X is independently selected from N or C.
The 8-(pyridinetriazole) substituted coumarin compound according to claim 1 or 2, wherein the 8-(pyridinetriazole) substituted coumarin compound is selected from the structure shown below:
The stereoisomer of the 8-(pyridinetriazole) substituted coumarin compound according to any one of claims 1-5, a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same;

Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable pharmaceutical excipients.
The preparation method of the 8-(pyridine triazole) substituted coumarin compound according to any one of claims 1-5, comprising:

Will
Mix with 3-(1-(2-oxo-2H-chromen-8-yl)-1H-1,2,3-triazol-4-yl)picolinic acid, and react to obtain; wherein, A ring The limited scope is consistent with the scope defined in any one of claims 1-5;

Its reaction formula is as follows:
The method for preparing 8-(pyridinetriazole)-substituted coumarin compounds according to claim 7, wherein the 3-(1-(2-oxo-2H-chromen-8-yl)- The preparation method of 1H-1,2,3-triazol-4-yl)picolinic acid comprises the following steps:

(1) 8- bromocoumarin is mixed with NaN , reacts to obtain 8-azidocoumarin;

(2) Mix 8-azidocoumarin with 3-ethynylpicolinic acid and cuprous iodide, and react to obtain 3-(1-(2-oxo-2H-chromen-8-yl)- 1H-1,2,3-triazol-4-yl)picolinic acid;

Its reaction formula is as follows:
The 8-(pyridine triazole) substituted coumarin compounds according to any one of claims 1-5 or the 8-(pyridine triazole) substituted coumarin compounds according to claim 6 Use of a stereoisomer, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same in the manufacture of a medicament for the treatment and/or prevention of a disease or condition associated with excessive SIRT2 activity or SIRT2 overexpression.
The use according to claim 9, wherein the disease or condition related to the overactivity of SIRT2 or the overexpression of SIRT2 comprises Parkinson's disease, metabolic disease or tumor.